These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16029937)

  • 21. Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users.
    Nas T; Sargon MF; Celik HH; Keskin PO; Gürsoy RH; Biberoglu K
    Saudi Med J; 2007 Dec; 28(12):1917-9. PubMed ID: 18060233
    [No Abstract]   [Full Text] [Related]  

  • 22. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy.
    Antunes A; Costa-Paiva L; Arthuso M; Costa JV; Pinto-Neto AM
    Maturitas; 2007 Aug; 57(4):415-21. PubMed ID: 17587515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tibolone on audiologic functions in menopausal women.
    Köşüş N; Köşüş A; Turhan NÖ; Kurtaran H
    Climacteric; 2011 Apr; 14(2):262-7. PubMed ID: 20690865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
    Kesim MD; Aydin Y; Atis A; Mandiraci G
    Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian cyst formation in patients using tamoxifen for breast cancer.
    Metindir J; Aslan S; Bilir G
    Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
    Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
    J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
    [No Abstract]   [Full Text] [Related]  

  • 29. [Endometriosis during postmenopausal period--probable causes for its origin and development].
    Nikolov A; Dimitrov A; Iliev D; Genov N
    Akush Ginekol (Sofiia); 2004; 43(6):50-3. PubMed ID: 15669654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen.
    Klaassens AH; van Wijk FH; Hanifi-Moghaddam P; Sijmons B; Ewing PC; Ten Kate-Booij MJ; Kooi GS; Kloosterboer HJ; Blok LJ; Burger CW
    Fertil Steril; 2006 Aug; 86(2):352-61. PubMed ID: 16828477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
    Jamin C; Bourg F; Legeai J; Senoussi S
    Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The need for tissue selective menopausal agents.
    Eden J
    Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication.
    Gregersen N; Jensen PT; Giraldi AE
    Dan Med Bull; 2006 Aug; 53(3):349-53. PubMed ID: 17092454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women.
    Filho AM; Barbosa IC; Maia H; Genes CC; Coutinho EM
    Gynecol Endocrinol; 2007 Sep; 23(9):511-7. PubMed ID: 17943546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy in women with past history of endometriosis.
    Soliman NF; Hillard TC
    Climacteric; 2006 Oct; 9(5):325-35. PubMed ID: 17000581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
    Diaby V; Perreault S; Lachaine J
    Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endometrial hyperplasia involving endometrial polyps: report of a series and discussion of the significance in an endometrial biopsy specimen.
    Kelly P; Dobbs SP; McCluggage WG
    BJOG; 2007 Aug; 114(8):944-50. PubMed ID: 17565613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.